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Abstract 
This Degree Final Project is based on the bibliographical search of the active pharmaceutical 
ingredient (API) firocoxib from a pharmacological point of view including the mechanism of 
action, indications or contraindications among others. 
Through a great search in biomedical literary bases such as PubMed and Scopus, the indications 
of this active pharmaceutical ingredient are supported with studies. In addition to investigating 
the new properties and indications that are currently being carried out and that are not 
described in its Summary of Product Characteristics. 
Next, the formulation of Previcox® 57mg is studied in detail, the only veterinary medicine with 
the same dosage and pharmaceutical form indicated in this project. Moreover, a proposal of the 
industrial manufacture of medicine in a study is made. Detailing the composition for each 
component. 
Finally, a new secondary packaging is designed. As a consequence, changes in primary 
packaging are produced. Resulting in a reduction of materials used and a more attractive design 
at an environmental level. 
 
Se realiza este Trabajo de Final de Grado basado en la búsqueda bibliográfica del principio 
activo firocoxib desde el punto de vista farmacológico incluyendo el mecanismo de acción, 
indicaciones o contraindicaciones entre otros. 
Mediante una gran búsqueda en bases literarias de ámbito biomédico como son PubMed  y 
Scopus, se respalda con estudios las indicaciones de dicho principio activo. Además de indagar 
en las nuevas propiedades e indicaciones que se están llevando a cabo actualmente y que no se 
encuentran descritas en ficha técnica del producto. 
Seguidamente se estudia con detalle la formulación de Previcox® 57mg, único medicamento 
veterinario con la misma dosis y forma farmacéutica indicada en este trabajo. También, se 
realiza la propuesta de fabricación industrial del medicamento en estudio. Detallando la 
composición por cada componente. 
Por último, se diseña un nuevo envase secundario, como consecuencia se producen cambios en 
el envase primario. Dando como resultado una reducción de materiales utilizados y un diseño 
más atractivo a nivel medio ambiental. 
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Scopes involved 
As the main scope, pharmaceutical technology is present in all parts of the project. But, it has 
the majority of implication in the dosage form, manufacturing process and packaging 
improvement.  
As  secondary scopes, biopharmacy and history and legislation. Pharmacokinetic and 
pharmacodynamic information of firocoxib are part of the biopharmacy field. This related 
information is explained in the section of the active pharmaceutical ingredient description. 
History and legislation are involved in firocoxib 57 mg chewable tablet project as laws and 
regulation of veterinary drugs by EMA (European Medicines Agency) and AEMPS (Agencia 
Española del Medicamento y Productos Sanitarios). History of NSAIDs is explained too. Strictly, 
it has no relation with the molecule of study but has a direct connection with the therapeutic 
group.        
1 Introduction 
The degree final project causes the student to see the large dimension of the pharmaceutical 
field and the areas covered by this knowledge. In particular, the work that I will present to you 
makes the student have a view from the molecule that produces the pharmacological action to 
the final product.  
This subject (Degree Final Project) puts into practice the capacities of autonomous work, 
compression of articles and the search of them in a careful way and in reliable and credible 
pages. It also exposes the student to a situation that can be found in the professional world 
where it will be necessary for the realization and/or exhibition of projects. 
The choice of this subject as my degree final project is based on the interest that I have in 
pharmaceutical technology. As the desire to continue specializing in this direction at the end of 
the degree. 
It also integrates other subjects or areas such as biopharmacy and history and legislation. In 
the first, we will discuss drug related topics at the animal organism level. While the second 
material is crucial in all the pharmaceutical aspects, among which we find the packaging or 
product controls. 
2 Objectives 
The realization of this project is based on the below objectives: 
 To review the pharmacology theory of analgesic drugs 
 To delve into the subgroup coxib 
 To search for veterinary studies 
 Study of the drug market with the same indications at the state level 
 To study the pharmaceutical form and its components. 
 Proposing an industrial process of the active pharmaceutical ingredient firocoxib 
 Making a new secondary packaging 
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3 Planning design 
The project was carried out from the end of January until May of 2019.  
During the months of January and February, the vast majority of searches of bibliographical 
references were carried out. These references belong to databases such as PubMed and Scopus 
as well as other reputable and reliable websites. All the notes related to the topics covered in 
this project were also located. The information collected was organized in folders according to 
the topics that they referred to. But not all of the information is included, as some documents 
were finally unrelated to the topics being attended.  
The beginning of the writing process took place during the last week of February and the whole 
month of March and April, including some weeks of May. Until the delivery of the work, reviews, 
corrections or decoration of the document were made. 
 4 Pharmacological view 
4.1 Pain 
Pain is an unpleasant feeling that is conveyed to the brain by sensory neurons. Discomfort 
signals, actual or potential, damage the body. Also, the perception of pain gives information on 
the location of pain and its intensity. 
4.1.1 Analgesic 
Analgesic refers to any drug that reduces pain without blocking the conduction of nerve 
impulses, altering sensorial perception or affecting consciousness. This selectivity differentiates 
them from anaesthetics. Analgesic might be classified into two groups: anti-inflammatory drugs 
and opioids or narcotics. The first classified should be used for short-term pain and for 
moderate pain. The second group is related to severe pain, short-term or long-term either.  
4.1.2 Anti-inflammatory analgesic  
Most current anti-inflammatory analgesics are derived from three compounds discovered in the 
19th century(1): 
                                                                          
 
 
 
 
A derivation of the first structure gives rise to develop acetylsalicylic acid. It is considered as the 
prototype for anti-inflammatory analgesic or non-steroidal anti-inflammatory drugs (NSAIDs). 
4.1.2.1 Non-steroidal anti-inflammatory drug (NSAID) 
NSAID reduces inflammation and is effective to treat pain and fever. Inflammation is the 
process of how the body protects against irritation or injury. Signs of inflammation such as 
redness, pain, swelling and warmth.  
Figure 1: Molecular 
structure of Salicylic 
Acid (2) 
Figure 2: Molecular 
structure of 
Pyrazolone (3) 
Figure 3: Molecular 
structure of 
Phenacetin (4) 
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NSAIDs are used to treat several symptoms, for example osteoarthritis, muscle aches, 
tendonitis or rheumatoid arthritis. 
NSAIDs inhibit the synthesis of prostaglandins (chemical product of inflamed white blood cells) 
that induce pain and inflammation. For this reason, it blocks cyclooxygenase (COX), an enzyme 
responsible for the synthesis of prostaglandins and related compounds(5,6). 
Also, they must be differentiated of corticosteroids that are steroid hormones, with capacity to 
reduce inflammation in the body. These have a lot of side effects such as fluid retention, high 
blood pressure, headache or facial hair growth. 
 
 
 
 
 
 
 
 
 
 
 
Each prostanoid has a particular function(9): 
 TxA2 (Thromboxane A2): platelet aggregation, vasoconstriction. 
 PGD2 (Prostaglandin D2): sleep/wake cycle, pain. 
 PGF2 (Prostaglandin F2): reproduction and vasoconstriction. 
 PGE2 (Prostaglandin E2): gastrointestinal protection, regulates body temperature, renal 
homeostasis, inflammation and pain. 
 PGI2 (Prostaglandin I2 or prostacyclin): vasodilatation, inhibits platelet aggregation, 
renal homeostasis, inflammation and pain. 
4.1.3 Cyclooxygenase enzyme  
It is known that it has two different isoenzymes. Both COX isoforms use arachidonic acid as an 
endogenous substrate; however each one from a different source and form the same products 
by the same catalytic reaction(7, 8). 
 
 
Essential fatty acids 
Membrane Phospolipids 
Phospolipase A2 
Arachidonic Acid Leukotriens 
Lipoxygenase 
Cyclooxygenase (COX) 
Steroids 
NSAIDs 
Prostaglandin H2 (PGH2) 
Prostacyclin (PGI2) Prostaglandins 
(PGE2, PGF2, PGD2) 
Thromboxane A2 
Figure 4: Prostaglandin synthesis (5) 
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Properties COX-1 COX-2 
Proposed role Physiological housekeeping Inflammatory response 
Amino acid 
homology within 
the same species 
60% 60% 
Intracellular 
localization 
Endoplasmic reticulum membrane 
and nuclear envelope 
Nuclear envelope and endoplasmic 
reticulum membrane 
Regulation Constitutive Inducible 
Range of 
expression 
2 to 4 fold 10 to 80 fold 
Tissue expression Platelets, endothelial cells, 
stomach, kidney, smooth muscle, 
most tissues 
Most tissues, especially inflammatory 
cells. Requires stimulation by growth 
factors, cytokines and hormones 
 
4.2 Mechanism of action and selectivity 
Nowadays, NSAIDs can be separated into two groups: non-selective NSAIDs and selective COX-
2 inhibitors.  
 
  
 
 
 
 
 
Also, COX inhibition produces adverse effects. In gastrointestinal mucosa, the COX- 1 inhibition 
reduces PGE2 synthesis, as a result mucus and bicarbonate secretion decrease such as peptic 
ulcers and gastrointestinal bleedings. This situation can be worse if the person has an infection 
of Helicobacter Pylori, which increases developing duodenal ulcers. 
Kidneys are mediated by COX-1 and COX-2, its block produces retention of water and sodium, 
hypertension and hemodynamic injury due to a reduction of vasodilator PGs of the afferent 
arteriole. Furthermore, this side effect reduces glomerular filtration rate (GFR).  
Figure 5: Differences between COX-1 and COX-2 (8) 
COX 
COX-2 - Expressed during 
inflammatory process 
 
COX-1 - Constitutively 
expressed 
 
Vasoconstriction 
Platelet aggregation 
 
Vasodilation 
Gastroprotection 
 
Nonselective NSAIDs 
Selective COX-2 inhibitor 
Figure 6: Mechanism of COX inhibition(10) 
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At last, the cardiovascular system whose inhibition had a stroke and myocardial infarction is 
most common with COX-2 inhibition than COX-1. In the normal situation, a balanced effect 
between PGI2 controlled by COX-2 endothelial and TXA2 controlled by COX-1 platelet exists. 
PGI2 produces vasodilatation and inhibits platelet activation. In contrast, TXA2 produces 
vasoconstriction and platelet aggregation. When the balance is in favour of TXA2, it happens 
after selective inhibition of COX-2 and vasoconstriction and platelet clumping can occur(11). 
4.2.1 Coxib 
Coxib is the suffix used to refer to of selective COX-2 inhibitors. It was researched to keep 
antiinflammatory and analgesic activities, reducing at the same time gastrointestinal pain due to 
no inhibition of COX-1. The large side effect is platelet aggregation.  
In Spain, from 2002 to 2006 a health inspection visa for dispensing of these medicinal products 
was necessary. This produced a decrease prescription of coxib during these years. Furthermore, 
the Agencia Española del Medicamento y Producto Sanitario (AEMPS), the Spanish health 
administration, publish alerts with recommendations of risk and recommendable use of selective 
COX-2 inhibitors(12, 13).  
Firocoxib 
Firocoxib is a preferential COX-2 inhibitor for veterinary, 380 fold selectivity for this isoenzyme 
in the dog compared to COX-1 isoenzyme. The concentration of firocoxib required to inhibit 
50% of the COX-2 enzyme (IC50) is 0,16 (± 0,05) μM, whereas the IC50 for COX-1 is 56 (± 7) 
μM. 
The molecular formula is C17H20O5S, its IUPAC (International Union of Pure and Applied 
Chemistry) name is 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-
one and the CAS (Chemical Abstracts Service) number is 189954-96-9, useful to search in 
DrugBank database. 
The most relevant properties are molecular weight 336.402 g/mol, 0 hydrogen 
bond donor count, 5 hydrogen bond acceptor count and a logP of 2.98 (it has a 
low affinity for fat tissue). This drug satisfies Lipinski's laws(14, 15).  
After oral administration firocoxib is rapidly absorbed and the time to maximal 
concentration (Tmax) is 1,25 (± 0,85) hours. The maximal concentration (Cmax) is 
0,52 (± 0,22) μg/ml, area under the curve (AUC24
0) is 4,63 (±1,91) μg·hr/ml, and 
oral bioavailability is 36,9 (± 20,4) percent.  
The elimination half-life (t½) is 7,59 (± 1,53) hours. 96 % of firocoxib is bound to 
plasma proteins. The steady state, after multiple oral administration, is reached 
by the third daily dose. Firocoxib is metabolised by dealkylation and 
glucuronidation in the liver. Elimination is principally in the bile and 
gastrointestinal tract(16). 
No data relating to the use of firocoxib in humans were available. Adverse cardiovascular 
effects in humans have been considered with studies on firocoxib. In animals, studies don't 
show an increase in cardiac toxicity undergoing treatment with this molecule.  
However, lower concentrations of residues in animal organisms are not expected to cause 
cardiovascular risk to public health(17). 
Figure 7: Molecular 
structure of Firocoxib(14) 
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Drugs can be divided by their selectivity for COX isoenzymes. The table below includes the most 
used NSAIDs in veterinary. 
Selectivity Drugs 
Preferential or selective COX-1 
inhibitors 
Aspirin, Ketoprofen (cat), Vedaprofen, 
Tepoxalin, Flunixin (cow) 
Non-selective COX inhibitors S-Caprofen (horse), Flunixin, Ketoprofeno, 
Meloxicam, Phenylbutazone, Tolfenamic acid, 
Vedraprofen 
Slightly or moderately selective COX-2 
inhibitors 
S-Caprofen (dog, cat), Deracoxib, Etodolac , 
Eterocoxib, Mavacoxib, Tolfenamic acid, 
Meloxicam 
Highly or very highly selective COX-2 
inhibitors 
Cimicoxib, Firocoxib, Robenacoxib, Valdecoxib 
 
 
4.3 The clinical experience of firocoxib 
4.3.1 Indications 
Firocoxib was approved by EMA and FDA (Food and Drug Administration). The drug can be 
used in horses as an oral paste and for dogs as tablets.  
In Europe, firocoxib has been approved following Directive 2001/82/EC on the Community code 
relating to veterinary medicinal product(19) with the aim to establish laws for authorization, 
manufacturing, supervision, sale, distribution and utilization of veterinary drugs in the European 
Union (EU).   
However, this directive has suffered some modifications. Regulation (EC) No 596/2009(20), 
Directive 2009/53/EC(21), Regulation (EC) No 470/2009(22), Directive 2009/9/EC(23), Directive 
2004/28/EC(24) and Regulation (EU) 2019/6(25). 
Two indications were declared by firocoxib's producers focused on dogs. Firstly, relief of pain 
and inflammation associated with osteoarthritis. Secondly, relief of post-operative pain and 
inflammation associated with surgery of soft tissue, orthopaedics and dental. 
Osteoarthritis 
Osteoarthritis is a chronic disease characterized by loss of articular cartilage that has the 
function of protecting the ends of bones in joints of the body, as a result, bones don't friction 
among them. In dogs, osteoarthritis is the most common form of arthritis, affecting one of 
every four animals.  
Different factors can affect the development of the disease (age, sex, obesity or breed). 
However, some studies demonstrated that there could be other predisposed factors:  
 Males develop osteoarthritis in more level than female. This could be due to sex 
hormones or the differences of bodyweight(26).  
 Neutered dogs have more predisposition to develop joint disease due to the reduction 
of gonadal hormones acting against osteoarthritis(27). Another presumption is the 
association of neutering with weight gain(28).   
Figure 8: COX inhibitors selectivity(18) 
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In general, it appears as a second disease, being the first an orthopaedic disease such as hip 
dysplasia, elbow dysplasia, among others. The joints that principally are affected are the hip, 
stifle and elbow.   
The most characteristic signs and symptoms are: normal activity reduction and stiffness, 
lameness or inability to jump can appear. And pain when a person manipulates, changes in its 
behaviour such as aggression or discomfort.  
Osteoarthritis is commonly diagnosed when mobility is too affected. In general, more than 50% 
of diagnosed dogs are aged from 8 to 13 years(29,30). 
Treatment consists of pain medication, physical modalities, exercise routine to lose extra-weight 
and nutritional support and physical rehabilitation as a way to improve mobility(31). 
Postoperative pain 
NSAIDs or coxib are safe and effective to treat this kind of pain. They should be administered to 
all cases unless specific patients in which administration is contraindicated. The use of these 
drugs help to decrease opioid requirements.  
Which type of NSAIDs or coxibs is prefered depends on various factors such as cost 
effectiveness, duration and modality of administration. Neither side effects or complications are 
unusual in the postoperative period. Safety varies for each drug, dose and duration(32,33). 
Soft tissue surgery  
Soft tissue surgery refers to any surgery of muscle, fat, fibrous tissue or blood vessels, it can 
cause mild, moderate or severe postoperative pain. It depends on the severity of the 
postoperative condition and the localization and magnitude of the surgery.  
 Orthopaedics surgery  
Orthopaedics surgery treats acute injuries, congenital and acquired disorders and chronic 
arthritis or overuse conditions of bones and joints. 
Both indications (soft tissue and orthopaedics surgery) are very similar, NSAIDs are able to 
reduce pain in three levels: mild, moderate and severe. But, in major surgery or in a specific 
case it could be possible to add or replace it for another drug, for example opioid. Also, pain 
relief would need more or less dose. However, each post-operative surgery has its specific 
protocols (34).  
Dental surgery 
Oral or dental surgery is related to the tissues of the mouth, including teeth and gums.  
NSAIDs and OTC (Over The Counter) products that are prescribed by dentists could be a 
sufficient analgesic to treat the pain of postoperative surgery(35). 
4.3.2 Firocoxib studies indications 
Efficacy and Safety of Firocoxib for the Treatment of Pain Associated with Soft 
Tissue Surgery in Dogs under Field Conditions in Japan(36) 
The study highlights the use of firocoxib to treat postoperative pain. A total of 131 dogs 
were divided into two different groups, one treated with firocoxib and the other non-
treated with firocoxib. The evaluation of pain took place on Day 0 before the surgery 
through Day 2. 
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Firocoxib treatment consists of doses of 5mg/kg on Day 0 before the surgery and once 
daily through Day 2. 69 dogs took part in the study, 62 of these dogs are the group 
non-treated with the drug. 
The success variable based on if the dog needed rescue medication (under pain 
assessment or Investigator's judgment) between the groups had a significant 
difference: firocoxib-treated ,16,4%, and non-treated, 50,0% (P=0,0031) was 
observed.  
The effects of firocoxib (Previcox®) in geriatric dogs over a period of 90 days(37) 
The study evaluated the effects of firocoxib administered to geriatric dogs with 
osteoarthritis over seven years of age for 90 days. Lameness and pain had been 
evaluated by the owner weekly in the first month and biweekly the last two months. At 
the same time, biochemical parameters have been controlled such as urea, creatinine or 
alanine transferase.  
Initially, the study started with 45 dogs into the treatment group and 9 into the control 
group. Finally, it finished with 33 dogs in the treatment group and 8 in the control 
group.  
Between days 0 and 90, bile acids and urea were significantly different in the treatment 
group. Furthermore, urea and creatinine on day 90 were significantly different between 
treatment and control group. As a conclusion, the study showed that firocoxib was 
effective to reduce pain associated with osteoarthritis for 90 days. 
Long-term efficacy and safety of firocoxib in the treatment of dogs with 
osteoarthritis(38) 
The study enrolled 29 dogs with osteoarthritis treated with 5 mg/kg, daily for 52 weeks. 
Finally, 25 dogs completed the study; the withdrawal rate associated with 
gastrointestinal adverse effects was 5,1%. At the end of the study, 96% of the 25 dogs 
that completed the study had improved under the owners' assessment. 
Between day 90 and day 360, 48% of the 25 remaining dogs improved their lameness 
(P<0.005). 
4.3.3 Firocoxib studies comparison  
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate 
crystal induced synovitis model of arthritis in dogs(39) 
This study compares different NSAIDs after induced synovitis at three and seven hours. 
Firocoxib, carprofen and vedaprofen will be compared. This comparison is formed by 
two evaluations: peak vertical ground reaction force as the most important variable and 
the punctuation of lameness extremity. 
Administration of a very selective COX-2 inhibitor, like firocoxib, decreases the pain 
produced by synovitis and improves significantly the capacity to support the weight at 
doses that the manufacturer recommend (5,0 mg/kg).  
As a conclusion of the study, firocoxib has significant differences with carprofen and 
placebo, but not with vedaprofen.  
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Post-operative analgesic effects of butorphanol or firocoxib administered to dogs 
undergoing elective ovariohysterectomy(40) 
Comparison between butorphanol or firocoxib as analgesic medication post-surgery. 
Twenty-five dogs were enrolled in the study, 12 of them in the butorphanol group and 
the rest in the firocoxib group. Animals were treated with respective drug after surgery 
and their pain evaluated using the dynamic and interactive visual analog scale (DIVAS). 
Rescue analgesia was morphine and firocoxib if DIVAS> 50. 
As a result of the study, firocoxib group had significantly lower pain scores than the 
butorphanol group (p<0,05). Rescue analgesia was used to 11/12 in the butorphanol 
group and 2/13 in the firocoxib group (p<0,05).  
Comparison of the analgesic efficacy of perioperative firocoxib and tramadol 
administration in dogs undergoing tibial plateau leveling osteotomy(41) 
Administration of tramadol, firocoxib or tramadol-firocoxib were evaluated for signs of 
pain and limb function. Thirty dogs enrolled in this study, they were divided between 
three possible treatments (10 in each group). 
As a result, treatment with firocoxib or the combination firocoxib-tramadol is useful to 
reduce the pain as it could be seen in lower pain scores. Furthermore, limb function 
was better than dogs which received only tramadol. The use of tramadol only may not 
provide sufficient analgesia to treat post-operative orthopaedic pain in dogs. 
4.3.4 Contraindications 
Firocoxib should not be administered during gestation and lactation. Neither in dogs with less 
than 10 weeks of life or less of 3kg of weight. It should not be used in animals with some of the 
following diseases: gastrointestinal bleeding or bleedings disorders and dyscrasia. Or if the 
animal has a treatment with another NSAIDs or corticoids(16).  
4.3.5 Interactions 
Treatment with firocoxib needs to avoid administration at the same time with other NSAIDs. For 
this reason, animals have to maintain a period of 24 hours without any other treatment. The 
administration of both medications could aggravate or side effects could appear.  
There will be interaction when administered with molecules that action renal flow, such as 
diuretics or angiotensin-converting enzyme inhibitors (ACEI). Also, nephrotoxic active 
pharmaceutical ingredient must be avoided because it can increase the risk of renal toxicity. 
Firocoxib has a high degree of protein bindings, concomitant administration with a drug that 
has a high degree of binding can produce toxicity effects due to a fact of competition between 
them(16).  
4.3.6 Side effects 
Generally, emesis and diarrhoea are transitory and reversible when withdrawing the treatment. 
In rare occasions, it can produce nervous system disorders. In very rare occasions, it can 
produce hepatic and renal disorders.  
If one or more of the following side effects occur the use of the product must be left off: 
vomiting, repetitive diarrhoea, hidden blood in the stool, spontaneous loss of weight, anorexia, 
lethargy and alteration of parameters biochemistry renal and hepatics(16).  
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4.3.7 Precautions for humans 
In SmPC (Summary of Product Characteristics) of Previcox® it is possible to see a specific 
paragraph that contains the precautions for the person who gives the medicine or comes into 
contact with the animal. These precautions are(16): 
 If the person ingests the medicine as an accident, this person should be visited by a 
physician and show the package leaflet or the label. 
 Wash hands after manipulating the product. 
 Use gloves to take the tablet. Avoid contact with skin or eyes. If it occurs, wash the 
area with water. 
4.4 The last advances with firocoxib 
Although firocoxib and selective COX-2 inhibitors have shown having chemotherapy 
characteristics, it doesn't appear in SmPC. 
4.4.1 Mechanism of action 
The inhibition of COX-2 produces an increment of arachidonic acid that stimulates the 
conversion of sphingomyelin to ceramide, a mediator of apoptosis. Also, it can produce 
apoptosis by the alteration of prostaglandins production and diminution of angiogenic factors.   
The mechanism is no dependent of the cyclooxigenase, it includes the inhibition of the 
activation of transcriptional factor NF-κB, interference of the union of nuclear hormonal receptor 
PPAR and the diminution of antiapoptotic gene expression BCL-XL. 
In mouse experimental tumoral study, after administration of coxib, cell proliferation decreases 
and the apoptosis increases (42).  
4.4.2 Studies 
Combination of radiation therapy and firocoxib for the treatment of canine nasal 
carcinoma(43) 
Twenty-four dogs were randomized to administrate the combination of firocoxib and 
radiotherapy (Group 1) or placebo and radiotherapy (Group 2). Dogs were monitored 
and pet owners completed a quality-of-life questionnaire monthly.  
As a result, not having differences statistically significant between the two groups in 
terms of median progression-free interval and overall survival. However, quality of life, 
which was evaluated with questionnaires, was significantly improved in Group 1 
(P=0,008). As a conclusion, firocoxib combination with radiotherapy is safe and 
enhanced life quality. 
 
Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor 
versus chemotherapy: a case-control prospective study(44) 
Twenty-eight dogs were enrolled and evaluated the disease free survival and overall 
survival. Dogs were randomized into two treatment groups mitoxantrone or firocoxib. 
As a conclusion, firocoxib's treatment had significantly higher disease-free survival 
(P=0,0015) and overall survival (P=0,048) than control dogs.  
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Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with 
transitional cell carcinoma of the urinary bladder(45) 
Forty-four dogs were enrolled in this study and randomized in three groups to receive 
cisplatin, firocoxib or a combination of both. Assessing tumor size, renal function and 
toxicoses. 
As a result, the remission rate of the combination (57%) had a significantly difference 
(P=0,021) in comparison with cisplatin alone 13%. Renal and gastrointestinal toxicoses 
didn't show significant differences between dogs which received cisplatin or 
cisplatin/firocoxib. As a firocoxib alone, partial remission was of 20% and stable disease 
was of 33%. 
Firocoxib alone can be useful as a palliative treatment for dogs with transitional cell 
carcinoma. 
Canine malignant mammary gland neoplasms with advanced clinical staging treated 
with carboplatin and cyclooxygenase inhibitors(46) 
Twenty-nine female dogs enrolled in this prospective study and dogs were treated with 
different protocols: surgery, chemotherapy and cyclooxygenase inhibitors. The goal was 
to compare overall survival periods of dogs that were diagnosed with advanced 
mammary tumors. The overall survival of females with high COX-2 scores was shorter 
than females with low COX-2 scores. In a similar way, adjuvant treatments associated 
with surgery shared longer overall survival in comparison with surgery alone. 
5 Pharmaceutical technology 
As appears previously, firocoxib 57mg tablets was approved by EMA and AEMPS. It is 
commercialized under the name of Previcox® 57 mg chewable tablets for dogs in Spain. But, 
the brand of firocoxib is Previcox® in all kinds of presentations, oral paste for horses or 
chewable tablets for dogs. 
5.1 Study of marketing authorizations 
In AEMPS web site it is possible to search drugs that have been approved in Spain. Through the 
use of Centro de Información online de Medicamentos Veterinarios de la AEMPS (CIMAvet(47)), 
which is a tool in Spanish drug regulatory page to know the situation of veterinary medication.  
After a slow search, firocoxib is compared with other medications with the same indications and 
for dogs that are approved by AEMPS. But their situation can be discontinued temporally or 
provisionally for different reasons, such as administrative causes or risks for public health, 
animal health or environment, or marketed(34, 47, 48). 
All of them take part from list the ATCvet QM01A. Anatomical Therapeutic Chemical 
Classification System (ATC) is a drug classification system that classifies by active 
pharmaceutical  ingredient in accordance with the organ or system where it produces its 
therapeutic effect related to pharmacological and chemical characteristics. In the case of 
veterinary drugs, it receives the name of ATC veterinary or ATCvet.    
 
In the following table NSAIDs that have been approved with the same indications than 
Previcox® appear. Cimicoxib and mavacoxib are highlighted due to both are selective COX-2 
inhibitors and have the same presentation as firocoxib.  
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Drug 
Trade Name Licensed formulation COX-2 
selectivity 
Carprofen Canidryl / Carprox VET / 
Norocarp / Rycarfa 
20, 50 or 100 mg tablets Partial 
Carporal 40 or 160 mg tablets 
Carprodyl (discontinued) 20, 50, 100 mg tablets 
Carprodyl Quadri 50 or 120 mg chewable tablets 
Norocarp 20, 50 or 100 mg flavoured tablets 
Dolocarp Sabor / 
Rimadyl 
20, 50 or 100 mg chewable tablets 
Carprofelican / 
Carprogesic/ Norocarp / 
Rimadyl / Rycarfa / 
Carprox (discontinued) 
50 mg/ml solution for injection 
Cimicoxib Cimalgex  8, 30 or 80 mg chewable 
tablets 
Yes 
Firocoxib Previcox  57 or 227 mg chewable tablets Yes 
Ketoprofen Ketofen (discontinued) 5, 10 or 20 mg tablets Partial 
Ketofen (discontinued) 10 mg/ml solution for injection 
 
Mavacoxib 
 
Trocoxil 
 
6, 20, 30, 75 or 95 mg 
chewable tablets 
 
Yes 
Meloxicam Acticam (discontinued) / 
Inflacam / Loxicom / 
Metacam / Rheumocam 
1 or 2,5 mg chewable tablests Partial 
Acticam / Inflacam / 
Loxicom / Meloxidolor / 
Meloxidyl / Metacam / 
Rheumocam 
5mg/ml solution for injection  
Adocam / Inflacam / 
Loxicom / Melosus / 
Meloxidyl / Meloxoral / 
Metacam / Rheumocam 
1,5 mg/ml oral suspension  
Inflacam 1mg chewable tablets 
Loxicom / Metacam 
(discontinued) 
0,5 mg/ml oral suspension 
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Robenacoxib Onsior 10, 20 or 40 mg tablets Yes 
 Onsior 20 mg/ml solution for injection 
Onsior (discontinued) 5 mg tablets 
Tolfenamic 
acid 
Tolfedine 6, 20 or 60 mg tablets Partial 
Tolfedine / Tolfedol 40 mg/ml solution for injection 
 
 
5.2 Previcox® dosage form  
The formulation as a chewable tablet must be adequated to the hardness that is the necessary 
power to break the tablet, the disintegration that is the time for break up into small particles in 
more cases it is an important factor to prevent gastrointestinal obstructions, and dissolution 
which is essential a correct pH. Also, it should be palatable and an appropriate size and 
shape(49). 
Palatable dosage forms improve compliance and convenience of animals that are voluntarily 
accepted. In the case for dosage forms that are too chewy might not be consumed so freely 
even with complex palatants. The addition of aroma in the dosage form can help it to be more 
attractive to dogs. 
Palatable means the property of being acceptable to the mouth. There are two different types 
of palatability: acceptance (choice to consume or not) and preference (choice between two 
dosage forms).  
The studies will be carried out with chewable tablets without active pharmaceutical ingredient.  
The most critical test is the acceptance test, it is a direct measure of compliance of consuming 
the medication. Acceptance palatability compares four different complex palatant with placebo. 
The aim was conducted to investigate whether the addition of an aroma component improves 
acceptance. Sugar placebo is assumed to not have a high palatability. As a result, dosage form 
which included complex palatant with the goal to enhance the taste and smell approximately 
doubled the acceptance. When it compares the rate of partial or none consume with full 
consume, either of them was higher in placebo than complex palatants. Furthermore, treatment 
was not well accepted when the tablet was too chewy. To sum up, the mouth feel can also play 
a significant role. 
Moreover, in the acceptance study, the addition of aromatic ingredients did not increase 
significantly the prehension or the full consumption. Although, in preference study, choice of a 
tablet with aroma was, in general, more often than the control (sugar placebo)(50). 
Firocoxib is a chewable tablet with tan-brown colour and it has round, convex and engraved 
scored tablets. It must be administrated orally.  
For dogs with osteoarthritis, the veterinary has to administrate 5mg/kg once daily. The 
laboratory recommends care and regular control when it will be administrated for more than 90 
days. Post operatory pain administrate 5mg/kg once daily for three days, it can be necessary to 
start two hours prior to surgery. 
For orthopedic surgery, it would continue with the same dosage after the first three days. With 
veterinary acceptance(16). 
Figure 9: study market of NSAIDs in Spain (34, 47, 48) 
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Body weight Number of chewable tablets by 57 mg mg/kg range 
3.0 – 5.5 0.5 5.2 – 9.5 
5.6 – 10 1 5.7 – 10.2 
10.1 – 15 1.5 5.7 – 8.5 
 
 
The laboratory gives this schedule for this dosage. For dogs with a body weight over 15 kg it 
recommends to administrate the dosage of 227mg.  
5.3 Excipients of Previcox® 
 Silica, Colloidal anhydrous 
Colloidal anhydrous silica (known as colloidal silicon dioxide or Aerosil® too) is a 
microscopic silica with an approximately particle size of 15nm. Its characteristics are a 
bluish-white-coloured, tasteless, amorphous, light, loose and odourless powder. It is 
used in pharmaceutical formulation of tablets or capsules due to its small particle size 
but the large surface area that improves the flow properties of dry powder. It can act 
as many functions as an adsorbent, an anti-caking agent, an emulsion stabilizer, a 
suspending agent, a viscosity-increasing agent and a tablet disintegrant(52). 
 
 Hydroxypropylcellulose 
Hydroxypropylcellulose is a light yellow, tasteless and odourless powder. It is used in 
oral formulations as a binder, a film-coating and an extended-release matrix former. In 
concentrations of 2-6%, it is used in wet or dry granulation and in direct compression 
tableting processes as a binder. Moreover, in concentrations of 15-35%, it is used to 
produce extend-release drugs. The velocity of the release and viscosity of this 
substance are inversely proportional. Also, the addition of an anionic surfactant 
produces the increase in the viscosity of hydroxypropylcellulose resulting in a decrease 
in the release of the drug. To film-coat tablet, this may be used too, as a solution of 
5%. Other properties of this substance are that it can be used in microencapsulation 
processes and as a thickener agent(52). 
 
 Cellulose, Microcrystalline  
Microcrystalline cellulose (known as Avicel® too), is a purified cellulose and partially 
depolymerized. Its appearance is an odorless, tasteless, crystalline and white powder. 
Depending on porous particle sizes its properties and applications will be different. The 
most used property is as a diluent and blinder. Both of them can be used in wet-
granulation and direct compression processes of oral tablet or capsule. Also, this 
excipient has a lubricant and disintegrate behaviour that are good properties for 
tableting(52). 
 
 
 
 
 
Figure 10: dosage of Firocoxib 57mg(51) 
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 Lactose Monohydrate 
Lactose monohydrate appears as a variety of isomeric forms, it depends on the 
crystallization and conditions. The stable crystalline forms of lactose include lactose 
monohydrate conformation . Lactose looks like white crystalline particles or powder. It 
is sweet-tasting and odorless. Lactose monohydrate is used as a filler and diluent. Fine 
grades of lactose are commonly used in the wet-granulation method or when milling, 
due to its size it allows better mixing with the other substances and utilizes the binder 
with better efficiency(52). 
 
 Croscarmellose Sodium 
Croscarmellose Sodium appears as a white or light gray and odorless powder. It is used 
as a disintegrate for capsules, tablets or granules. In the second case, carmellose 
sodium might be used either direct-compression or wet-granulation(52). 
 
 Magnesium Stearate 
Magnesium stearate is a very fine, precipitated or milled, light white, impalpable 
powder with a low density. It has a characteristic taste and odor. Also, it adheres to the 
skin and for handling it has a greasy feel. It is used as a lubricant in capsules or 
tablets(52). 
  
 Iron Oxides 
A quite variety of iron oxides exist, its appearance depends on the particle size and 
shape, and crystal structure. It can be yellow, red, black or brown powder. Iron oxides 
are used as colorants and UV absorbents in pharmaceuticals formulations. In some 
countries, the quantities that may be consumed are restricted(52). 
  
 Caramel 
Caramel is used as a food colouring. Four different types exist E150a, E150b, E150c 
and E150d in Europe and Caramel Colors I, II, III, IV in America. E150d means caramel 
ammonium sulphite and it is the darkest of all the caramels. It is necessary to 
differentiate caramels for colouring and caramels for flavouring(53).   
 
 Chartor Hickory Smoke Flavour 
Aroma of smoked nut. 
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5.4 Manufacturing process 
Excipient Function  Percentatge Weight for tablet 
Silica, Colloidal anhydrous Glidant 0,5% 1,2mg 
Hydroxypropylcellulose Binder 4,0% 9,6mg 
Microcrystalline Cellulose Diluent 48,0%  115,2mg 
Lactose Monohydrate Diluent 15,0%  36,0mg  
Croscarmellose Sodium Desintegrant 3,0% 7,2mg 
Magnesium Stearate Lubricant 2,5% 6,0mg 
Iron Oxides Colorant 0,1% 0,24mg 
Carmel Flavour 0,15% 0,36mg 
Chartor Hickory Smoke 
Flavour 
Aroma 3,0% 7,2mg 
Firocoxib NSAID 23,75% 57,0mg 
Total weight 240mg 
 
List of excipients deduces that direct compression is the best way to produce firocoxib 57mg 
chewable tablets due to the fact that lactose monohydrate and microcrystalline cellulose are 
used in direct compression tablet. 
But hydroxypropylcellulose as a binder is used in wet granulation too. The use of binder in the 
direct compression process, enhances the capacity of flowability and compressibility(54). 
The manufacturing process consists of a sequential addition of the excipients and the active 
substance, with direct compression of the desired chewable tablet weight(17).  
Direct compression has many advantages such as cost effectiveness that direct compression 
requires few operations as a result of less equipment, lower source consumption, less space 
and time. It is an important type of compression when active pharmaceutical ingredient (API) 
needs to maintain the stability that it could not keep up with wet or dry granulation.  
Drugs that are produced by direct compression have a faster dissolution due to the fact that 
API disintegrates directly to particles instead of granules. Also, direct compression avoids the 
high pressure by slugging or roller compaction.  
And for a short period of time, less chance for contamination or cross contamination making it 
easier to satisfy Good Manufacturing Practices (GMP). At the same time, reducing the quantity 
of documentation that is required. No use of water decreases the possibilities to be 
contaminated by microbial growth.  
Figure 11: formulation of Firocoxib 57mg(16, 51, annexes) 
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Weighting 
The process starts with the weighting of all components (API and excipients) for producing a 
batch with a specific size. Previously, components must have passed quality controls to comply 
with the security and efficacy expected.  
Weighting takes place in an independent room where qualified operators use adequate scales to 
weigh every component and tag them. They will be stored in containers or bags(55).  
   
Sieving 
Firocoxib and excipients should have similar size, for this reason, all components have to use 
sieve machine to homogenize particle size. Components can be passed through a mesh of a 
specific size or through a cascade of decrease size. In general, for compression sieving is used 
as an optional step, but it is useful to do it since it reduces the possibility to have granules and 
little mass with a bigger size than the others. These machines use a vibrating system to sieve 
the substance. 
Nowadays, some machines incorporate mill and sieve steps. It has good advantages in contrast 
with conventional machines: it reduces process time, faster clean because one machine has to 
be cleaned not two, less lost components, among others. This system uses rotational harms to 
crash the granules and to ease the sieve process(55).  
                                  
 
 
 
 
 
 
Weighting  Mixing Compression Quality Controls 
Figure 12: direct compression process(55) 
Sieving 
Figure 13: Scale Baxtran TMM of 30 to 600KG(56) 
Figure 16: vibratory sifter diagram(57) 
Figure 17:  oscillating sieve(58) 
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Mixing 
In this point is when all the components of Previcox® get in touch. Except for the magnesium 
stearate that will be added a few minutes before the end of the mixing process. If it is added at 
the first moment, it could give problems of disintegration because magnesium stearate creates 
a coating that does not allow contact between water and mixing mass. Mixing machine is based 
on rotation movement to facilitate a homogenous mix powder.     
In the market a variety of mixers for the pharmaceutical industry exist, but three types of 
mixers are widely used.  
 Double Cone blender is a symmetric machine in its transverse and sagittal plane. It is 
usually used for the mixing of dry powders and granules homogeneously.  
 "V" shape blender is a symmetric machine in its sagittal plane. It is commonly used to 
mix powders. With rotational movement, the powders separate and come together, in 
contrast with double cone blender, where powders go together all the time. 
 Eliconomix is a vertical cone container inside a vertical screw that runs all the volume of 
the cone, producing an upward flow of product.  
                             
 
Mixers can include a system called "Clean-in-place" which means it cleans itself. This technology 
has a lot of advantages such as reducing the quantity of water and detergents in comparison 
with hand clean, it is an automatic system and it minimizes the cleaning time.  
The few disadvantages are the cost to install it and the technology that the system uses as 
professional staff to operate it is necessary (55). 
Compression 
The compression process uses high pressure to compact all components to create a tablet. 
Eccentric press and rotary press take part in this stage.  
On the one hand, the eccentric machine is used in pharmacy or in the first part of the 
development of the drug due to the fact that a big quantity of tablets is not necessary. On the 
Figure 18:  mill-sieve machine diagram(59) 
Figure 18:  eliconomix(60) Figure 19:  "V" shape blender(60) 
Figure 20:  double cone blender(60) 
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other hand, the rotary press is more extended used in pharmaceutical industry because of its 
power to manufacture a huge number of tablets per hour. 
The rotary press consists of a rotating system of punches, each station has a pair of punches 
oriented vertically (upper and lower). The modification of a parameter of purchase can change 
pressure, weight or hardness. Also, it could be possible to change the velocity of the system.  
Stages of compression: 
 Powder filling. It is a pre-compression stage. The powder will be charged in the hopper 
to feed the tablet press. 
  Powder metering. It consist of the precise filling of powder in the die cavity. It should 
be as precise as possible because excess powder can cause incidents in the following  
stages.  
Immediately after the filling, the punches of lower turret moves to a determined level 
and the excess of powder will be removed from the surface. This determined level has 
the function to fill the exact volume and weight of powders for compress and pass 
controls of tablet parameters.   
 Pre-compression and compression process. Pre-compression means to remove the air 
that has been trapped within the powder. For doing it, punches exert pressure but a 
little amount in comparison with the compression process. In the compression process, 
powders will be completely compressed in a tablet applying huge pressure for having 
the desired hardness.  
This stage takes place through pre-compression and compression roll. Either of them, 
upper punches go down to compress the powders. After compression, upper punches 
come back to their initial position.  
 Tablet discharged. Lower punches were already lifted up, pushes tablets out of the die 
cavity. Then, the scraped will remove the tablet to the discharge chute. 
The process of compression is continuous in which turret moves in a rotary way. In general, a 
complete revolution should match the number of tablets produced and the number of dies in 
the turret. If it is not equal, press machine maybe has had a problem with filling, compress 
stage or purchase, among others(55,61).   
Figure 21:  compression machine 
XL400MFP/SFP Korsch(62) 
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Quality Control 
When the manufacturing has finished, finished product quality controls take place. The dosage 
form of firocoxib is chewable tablets that have the same quality control test than tablets. But, 
the disintegration test is not necessary. These tests are listed below : 
 Organoleptic evaluation: tan-brown, round, convex, engraved scored tablets, slotted 
and smell of smoked walnut. 
 Content of active ingredient 
 Uniformity of content of active ingredients:  
 Uniformity of weight: as maximum two chewable tablets out of range 95-105% and 
none out of range 90-110%. If the average weight is 240 mg, the range of 95-105% is 
228-252 mg and the range of 90-110% is 216-264 mg. 
 Dissolution 
 Diameter 
 Friability: it is acceptable if it has a maximum loss of 1% of the weight and none of the 
tablets have been broken. In chewable tablet different specifications can be accepted.  
 Hardness: pharmacopeia accepts the results when the values are higher than 60N, for 
chewable tablets these values will be minor due to its dosage form and administration. 
 Uniformity of weight of slotted tablet (half-tablet) 
 Blister tightness 
 
If tablets pass all this quality control, they could be distributed and marketed after being 
packaged. At the moment that batches fail the quality control and specifications, an OOS (Out 
Of Specifications) will be opened and started an investigation to resolve the causes of this 
mistake. Also, the possibility to apply CAPA (Corrective Actions Preventive Actions) to reduce 
the number of future mistakes in the manufactured process(49,55,63,64). 
Moreover, this manufacturing process maybe includes in-process quality control. In-process 
quality controls allow to find out OOS in less time and reduce economic impact. In firocoxib's 
manufacturing, weight and hardness would be these parameters. However, it is important to 
have a strict follow up of the times in which these quality controls will be carried out(55, 65). 
Figure 22:  tablet making                                                                                
process machine(61) 
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Packaging 
It should be differentiated in primary and secondary packaging. The primary packaging product 
has the function of protection and keeps the integrity, for example, it could be a blister or a jar. 
The secondary packaging means the box where the primary packaging is introduced, it has to 
satisfy its corresponding law. 
Nowadays, it is easy to see an automatic process of packaging at the end of manufacturing 
chain medicine. Automatic blister machines are composed by a set of stages that will be defined 
below. 
Firocoxib 57mg (Previcox®) blisters are made of Alu/PVC, it means one side is aluminium and 
the other side of polyvinyl chloride. PVC will be defined as the forming film that forms the base 
of the blister pack and aluminium as the lidding material that covers the content of the cavity. 
Their locations in the machines are different because the PVC roller will be located at the 
beginning and the aluminium roller in the middle of the blister process. 
The forming film will then move to a heating station where the lower and upper plates form a 
uniform and consistent heating to carry the next stage on. Pocket forming consists to use either 
plates or compressed air to form cavities. After that, these should be cooled to form a rigid 
plastic cavity. The next stage is the filling with tablets, manual or automatic, and checking that 
all cavities are empty.  Followed by the coverage with the lidding material and the sealing with 
the application of temperature, it will be different depending on the material. The next station is 
an important stage because the information that will be printed in the blister occurs at this 
moment. Usually, the information that is engraved is information about the product such as 
dosage, expiry date, lot identification, route the administration and the name of the medicine as 
a manufacturer. Finally, the trimming stage pack products into individual units and eject from 
the machine(55,66,67).   
 
 
 
                                                                   
 
Figure 22:  flow chart of automatic packaging 
machine(67) 
Figure 23:  SaintyCo Blister Packing Machine(66) 
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6 Packaging improvement 
Old design 
The dimensions of the packaging of Previcox® 57 mg 10 tablets (the choice of this presentation 
is because it is the most practical in comparison with the other and for the owners it is the 
cheapest) are 11 cm x 4,8 cm x 2,3 cm (length x width x depth): 
 
 
 If the finality is to design new packaging that improves the current one, it is necessary to know 
how the blister was manufactured. Previcox® 57 mg 10 tablets only consist in one blister with 
the following dimensions: 10,2 cm x 4 cm x 0,5 cm.  
 
      
 
The first enhance of this product is to include expiry date and lot identification in every tablet 
because each one can be trimmed and separated from the rest of the blister. 
New design 
To design a new one it could be easy to reduce the depth of secondly packaging and make it 
tighter than the older. In the box, the information appears in three languages: English, Spanish 
and Greek. Keeping Spanish and English it is possible to reduce the length and modify the 
disposition of the blister in two blisters with five tablets each. 
 
 
                   Dimensions: 5,7 cm x 4 cm x 0,5 cm 
 
 
Figure 22:  Previcox 57 mg 10 tablets (Owner) 
Figure 23:  Previcox 57 mg 10 tablets (Owner) 
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The width of the current design is 1,0 cm larger than the width of the blister to ease its 
handling. In the new design, it can be useful to keep the same distance between the box and 
the length of the blister. For calculating the depth it is indispensable to remember that now the 
presentation consists of two blisters. For this reason, the depth of one of them needs to be 
multiplied by two and leave space for the leaflet. As the information of the product, in the box, 
the languages of the leaflet will be reduced from three to two, discarding Greek. Finally, the 
dimensions of the secondary packaging will be 6,5 cm x 4,8 cm x 2 cm.  
 
 Old design New design Reduction 
Length 11 cm 6,5 cm 40,91% 
Width 4,8 cm 4,8 cm 0% 
Depth 2,3 cm 2,0 cm 13,04% 
Area  178,28 cm2 107,6 cm2 39,65% 
 
It would be considered an eco-friendly improvement since the reduction of paperboard in 
comparison with the old design. Another environmental-friendly action would be the change of 
blister material, changing Alu/PVC for Alu/Alu. Aluminium is one of the materials that has been 
extensively recycled. In contrast, if the PVC combustion is not complete, it causes an increase in 
the level of dioxin in the atmosphere(68). 
The new design that is adequate with the regulations(25) is presented below. 
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                                              575987.6          
ES Uso veterinario, medicamento sujeto a prescripción veterinaria 
 Tratamiento del dolor e inflamación asociados a la osteoartritis en 
perros  Método de administración: 5mg/kg una vez al día  Vía oral 
EN For animal treatment only, to be supplied only on veterinary 
prescription  Pain and inflammation associated with osteoarthritis 
treatment in dogs  Administration method: 5mg/kg once daily  
Oral use 
 
 
   575987.6 
Osteocanis 57 mg    
              Firocoxib 
10 comprimidos masticables 
Vía oral 
 
Titular de la autorización de                                                                          
comercialización: Universitat de                                                                                              
Barcelona, Gran Via de les Corts Catalanes                                                                                                  
585, 08007 Barcelona (España)                                                                                      
                     
Marketing authorisation holder:                                                                                                           
Universitat de Barcelona, Gran Via de les                                                                                                                     
Corts Catalanes 585, 08007 Barcelona (Spain) 
 
10 comprimidos masticables                     10 chewable tablets                                                                                                                       
                                                                                                                                                             
No conservar a una temperatura          Do not store above 30ºC                                                                                                  
superior a 30ºC                                                                                                                                               
Mantener fuera del alcance de los        Keep out of the reach and sight                                                                                                                        
niños                                                           of children                                                                                                                                                                  
Leer el prospecto antes de usar            Read the leaflet before use 
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7 Conclusions 
 Firocoxib belongs to the subgroup coxib within the NSAIDs. It is only used in veterinary 
medicine and is formulated as a chewable tablet. 
 Previcox® 57mg is the only drug marketed in Spain that contains firocoxib as an active 
pharmaceutical ingredient. Despite this, there are a wide variety of drugs marketed with 
the same indications. 
 The main indication is the treatment of osteoarthritis as well as postoperative pain. 
Although new indications of this drug are currently being discovered. 
 The dosage of this medicine depends on the pain that the animal suffers and its 
duration. As a general rule, the amount to be administered is directly proportional to 
the weight: more weight more doses. 
 Through the study of excipients and their functions, it is determined that the industrial 
process performed is a direct compression. Developing all the steps that will be carried 
out, using new and last technology. 
 Design of a new packaging that allows a positive evolution, promoting the reduction of 
materials used as an approach to a responsible packaging with the environment. The 
primary packaging will also undergo changes to favor an eco-friendly attitude by 
changing the blister of Alu/PVC by another one exclusively of Alu/Alu. 
 I have decided to present this work in English because it is the communicative vehicle 
established in global communication. 
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9 Annexes  
To give an approximate quantity of each compound that has a single tablet the ten chewable 
tablets that the littler box of Previcox® contains were weighted in an analytical balance. The 
results are below: 
Balance: Santorius BP310P 
0,241g 0,240g 0,245g 0,237g 0,236g 
0,242g 0,240g 0,240g 0,237g 0,243g 
= 0,240g SD=2,846·10-3 
 
Before weights, the balance has been calibrated and regulated. As shown in the following 
pictures.  
            
 
 
 
 
 
 
 
 
 
 
Figure 24:  weight process (Owner) 
